Skip to main content

Table 1 Baseline demographic and primary indication for fully enrolled patients

From: BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study

Patient Characteristics

Patients

N = 77

Age at Enrollment (years ± SD)

62.1 ± 15.4

Gender

 Male

41 (53.2%)

 Female

36 (46.8%)

Height (in ± SD)

67.8 ± 4.8

Weight (lbs ± SD)

205.6 ± 7.9

BMI (kg/m2 ± SD)

31.4 ± 6.6

Race

 White

71 (92.2%)

 Black or African American

5 (6.5%)

 Not Specified

1 (1.3%)

Primary Indication for Insertion

 Management for known AT/AF

37 (48.1%)

 Diagnosis of unexplained syncope

17 (22.1%)

 Palpitations

8 (10.4%)

 Diagnosis of suspected AT/AF

6 (7.79%)

 Cryptogenic Stroke

4 (5.19%)

 Near syncope

3 (3.90%)

 Other cardiac arrhythmia

2 (2.60%)

Other Medical History

 AF

41 (53.2%)

 Atrial Flutter

14 (18.2%)

 Bradycardia

19 (24.7%)

 Cardiomyopathy

10 (13.0%)

 Hypertension

48 (62.3%)

 Hypotension

3 (3.9%)

 Syncope

20 (26.0%)

 Ventricular Tachycardia

5 (6.5%)

 Other AT

10 (13.0%)

History of Ablation

31 (40.3%)

 Ablation for AF

21 (27.3%)

 Ablation for Atrial Flutter

6 (7.79%)

 Ablation for Other AT

3 (3.90%)

 Ablation for Ventricular Tachycardia

1 (1.3%)

  1. Values are presented as n (%) unless otherwise indicated. AF atrial fibrillation, AT atrial tachycardia